Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib + Paclitaxel in TNBC
NCT02672475Phase 1Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Mar 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in triple-negative breast cancer (TNBC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Incidence of adverse events and Maximum Tolerated Dose up to 28 days. Started Mar 2016; status: completed.
02
Drugs
galunisertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02672475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672475.